Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2023 annual report, the company imports pharmaceutical medicines and cosmetic products into Georgia and sells them through pharmacy networks and wholesale.
| Line item | 2022 | 2023 | CAGR |
|---|---|---|---|
| Total Revenue | 5,019 | 4,227 | -15.8% |
| Total COGS | 3,822 | 4,263 | +11.6% |
| Gross Profit | 1,198 | 36 | nmf |
| Gross Margin | 23.9% | 0.9% | |
| 2,121 | 1,253 | -40.9% | |
| EBITDA | 923 | 1,290 | +39.8% |
| EBITDA Margin | 18.4% | 30.5% | |
| Total D&A | 196 | 114 | -41.5% |
| EBIT / Operating Income | 1,118 | 1,404 | +25.6% |
| Total Interest Expense | 144 | 192 | +33.0% |
| 325 | 537 | nmf | |
| Profit Before Tax | 937 | 2,133 | +127.6% |
| Total Income Tax | 0 | 0 | |
| Net Profit / (Loss) | 937 | 2,133 | +127.6% |
| Net Margin | 18.7% | 50.5% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →